StockNews.com initiated coverage on shares of BioLineRx (NASDAQ:BLRX – Free Report) in a research note issued to investors on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock.
BioLineRx Stock Performance
BioLineRx stock opened at $0.41 on Wednesday. The company has a debt-to-equity ratio of 1.34, a current ratio of 1.61 and a quick ratio of 1.49. The firm has a market capitalization of $32.38 million, a P/E ratio of -0.53 and a beta of 1.46. BioLineRx has a 1-year low of $0.39 and a 1-year high of $1.93. The company’s 50-day moving average is $0.58 and its 200 day moving average is $0.64.
BioLineRx (NASDAQ:BLRX – Get Free Report) last issued its quarterly earnings results on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.09. The business had revenue of $5.39 million during the quarter, compared to analysts’ expectations of $3.93 million. Research analysts forecast that BioLineRx will post -0.25 EPS for the current year.
Institutional Inflows and Outflows
About BioLineRx
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Recommended Stories
- Five stocks we like better than BioLineRx
- Short Selling: How to Short a Stock
- Texas Roadhouse Stock Steering for New Highs This Year
- What is a Dividend King?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- The 3 Best Retail Stocks to Shop for in August
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.